Skip to content

Insomniacs driving after use of sleeping medication

Residual effects of zopiclone 7.5 mg on cognition and driving performance in insomnia patients chronically using hypnotics

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON25980
Enrollment
48
Registered
2008-06-12
Start date
2008-08-15
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

insomnia (insomnie) use of hypnotics (slaapmiddelengebruik)

Interventions

Subjects receive a single oral dose of zopiclone 7.5 mg or placebo. Balancing of treatments will be accomplished by randomly assigning subjects to one of two treatment sequences (placebo – zopiclone o

Sponsors

Maastricht University
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Male or female 2. Aged 55 years or older 3. Possession of a valid driving license for 3 years or more (for >70 years: Possession of “Declaration of Appropriateness’ (in Dutch: Verklaring van Geschiktheid)) 4. Average driving experience of at least 3000 km per year over the last three years 5. Mentally and physically fit to drive 6. Signed Informed Consent Form 7. Good health, in the opinion of the medical supervisor, on the basis of a pre-study physical examination, medical history, vital signs, electrocardiogram, and the results of blood biochemistry, haematology, and serology tests, and urinalysis 8. For patients: complaints of insomnia

Exclusion criteria

Exclusion criteria: 1. History of drug or alcohol abuse 2. Presence of significant medical (e.g. cancer), neurological (e.g. dementia, epilepsy, Parkinson), or psychiatric disorders (e.g. psychosis, major depression) 3. Chronic use of medication that affects driving performance (such as anti-epileptics, anti-psychotics, anti-depressants, anti-parkinsonian medication), except hypnotics 4. Drinking more than 6 cups of coffee per day 5. Drinking more than 21 glasses of alcohol per week 6. Smoking more than 10 cigarettes per day 7. BMI over 30 kg/m² 8. For patients: Sleep-Related Breathing Disorders; Circadian Rhythm Sleep Disorders; Sleep-Related Movement Disorders

Design outcomes

Primary

MeasureTime frame
The main study parameter is Standard Deviation of Lateral Position (SDLP in cm) in the highway driving test.

Secondary

MeasureTime frame
- Highway driving test: Standard Deviation of Speed (SDSP in km/h) - Car following test: Time to Speed Adaptation (TSA, in ms), brake reaction time (BRT, in ms) and Standard Deviation of Headway (SDH). Cognitive and psychomotor tests: • 15-Word Learning Test (Immediate and Delayed Recall Scores, Speed and accuracy of Recognition); • Critical Tracking Task (Average lambda [in rad/s]); • Divided Attention Task (Tracking Error [in mm], Target Detection Time [in ms]; • Stop Signal Task (Go Reaction Time [in ms], Stop Signal Reaction Time [in ms]); • Psychomotor Vigilance Task (mean Reaction Time [in ms]; percentage of Lapses [in %]; • Digit Span Backward and Forward (Maximum Forward and Backward Score). • Subjective evaluations: Subjective alertness assessed by Visual Analogue Scales

Contacts

Public ContactTim R.M. Leufkens

Maastricht University Fac. of Psychology Dept. of Neuropsychology & Psychopharmacology PO Box 616

t.leufkens@psychology.unimaas.nl+31 (0)43 3881756

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)